Cargando…

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial

INTRODUCTION: This MONONOFU trial subgroup analysis evaluates the efficacy of lasmiditan across patient and migraine characteristics in Japanese patients with migraine. METHODS: MONONOFU trial was a multicenter, randomized, double-blind, placebo-controlled study. The patients were randomly assigned...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeshima, Takao, Komori, Mika, Tanji, Yuka, Ozeki, Akichika, Tatsuoka, Yoshihisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525364/ https://www.ncbi.nlm.nih.gov/pubmed/36138260 http://dx.doi.org/10.1007/s12325-022-02304-0

Ejemplares similares

Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial
por: Matsumori, Yasuhiko, et al.
Publicado: (2022)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
por: Tatsuoka, Yoshihisa, et al.
Publicado: (2021)

Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
por: Shibata, Mamoru, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
por: Igarashi, Hisaka, et al.
Publicado: (2022)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
por: Igarashi, Hisaka, et al.
Publicado: (2021)

Lasmiditan: A New Promising Drug in Migraine
por: Prakash, Sanjay, et al.
Publicado: (2021)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study
por: Shibata, Mamoru, et al.
Publicado: (2020)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies
por: Hirata, Koichi, et al.
Publicado: (2022)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

The safety and preventive effects of a supraorbital transcutaneous stimulator in Japanese migraine patients
por: Danno, Daisuke, et al.
Publicado: (2019)

Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study
por: Matsumori, Yasuhiko, et al.
Publicado: (2021)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019)

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
por: Lipton, Richard B., et al.
Publicado: (2020)

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study
por: Ashina, Messoud, et al.
Publicado: (2021)

Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis
por: Basutkar, Roopa Satyanarayan, et al.
Publicado: (2021)

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
por: Doty, Erin G., et al.
Publicado: (2022)

Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey
por: Kikui, Shoji, et al.
Publicado: (2020)

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study
por: Hirata, Koichi, et al.
Publicado: (2023)

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
por: Krege, John H, et al.
Publicado: (2019)

Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis
por: Ahsan, Marya, et al.
Publicado: (2022)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k22hmv5p82dk3h33ap63hijhh2